GOLDLINE PHARMACEUTICAL LIMITE is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 31 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 5.97 |
| ROE % · ROCE % | — · 40.0 |
| Debt / equity (x) | — |
| Cash from operations | 3 |
| Capex | (0) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 17 |
| Profit before tax | 4 |
| Net profit | — |
| EPS (₹) | 3.43 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Promoter buys 60,000 shares of Goldline Pharmaceutical via open market | ownership changes | medium | — | — |
| 2 Sept 2026 · Promoter Amol Mujumdar buys 18,000 shares of Goldline Pharma | ownership changes | low | — | — |
| 1 Sept 2026 · Promoter MD Amol Mujumdar buys 60,000 shares via open market | ownership changes | low | — | — |
| 31 Aug 2026 · AGM 2026: All 8 resolutions passed with 100 percent approval | board shareholder meetings | low | — | — |
| 29 Aug 2026 · Goldline Pharmaceutical holds 22nd AGM, first post BSE SME listing | board shareholder meetings | low | — | — |
| 29 Aug 2026 · Promoter Swapan Khandelwal buys 78,000 shares via open market | ownership changes | medium | — | — |
| 29 Aug 2026 · Promoter Swapan Khandelwal buys 78,000 shares (0.81%) of Goldline Pharma | ownership changes | medium | — | — |
| 7 Aug 2026 · Goldline Pharma publishes AGM notice and e-voting details in newspapers | compliance | minimal | — | — |
| 6 Aug 2026 · Record date set for e-voting at 22nd AGM on 29 August 2026 | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Book Closure from 23 Aug to 29 Aug for 22nd AGM | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 10.6 | 28.9 | 26 of 169 | 85% |
| ROCE | 32.1 | 10.8 | 8 of 183 | 96% |
| Market cap | 25 | 839 | 163 of 182 | 11% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
